Research Horizons


After 1 Year, Weekly Doses of Dupilumab Most Effective at Managing Eosinophilic Esophagitis

After one year of follow-up, a 65-center, 10-nation clinical study reinforces earlier findings that weekly dupilumab treatment for eosinophilic esophagitis (EoE) produces stronger histologic, symptomatic, endoscopic, and molecular improvements compared to treatment every two weeks. 

Results from the study, led by Cincinnati Children’s physicianscientist Marc Rothenberg, MD, PhD, and co-authored by Margaret Collins, MD, Division of Pathology, were published online Aug. 31, 2023, in The Lancet: Gastroenterology and Hepatology.

Dupilumab is a biologic that blocks the shared receptor component for interleukin 4 and interleukin 13, two cytokines known to be involved in pathogenesis of EoE. More information about this double-blind, randomized, placebo-controlled, phase 3 study can be found at, number NCT03633617

In addition to this study, the cover of the journal’s September print edition focuses on another research study led by Rothenberg and colleagues. Those findings, published online in June, report that the monoclonal antibody benralizumab successfully reduces eosinophil cell counts but does not improve the symptoms nor biomarker results for eosinophilic gastritis (EoG).

Read More: Wider Search Needed to Better Treat Eosinophilic Food Allergy


Publication Information
Original title: Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Published in: The Lancet: Gastroenterology and Hepatology
Publish date: Aug. 31, 2023
Read the Study

Research By

Marc Rothenberg, MD, PhD
Marc Rothenberg, MD, PhD
Director, Division of Allergy and Immunology

The Rothenberg CURED Research Laboratory, supported by the Campaign Urging Research for Eosinophilic Diseases (CURED), is focused on elucidating the mechanisms of allergic responses, especially in mucosal tissues such as the gastrointestinal tract and lung.